EMMA (Emmaus Life Sciences) Net Margin %: -168.26% (As of Mar. 2026)


What is Emmaus Life Sciences Net Margin %?

Emmaus Life Sciences EMMA -16.67% Net Margin % is -168.26% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 947 Biotechnology companies, Emmaus Life Sciences ranks better than 51.74% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Emmaus Life Sciences's Net Income for the three months ended in Mar. 2026 was $-3.34 Mil. Emmaus Life Sciences's Revenue for the three months ended in Mar. 2026 was $1.98 Mil. Therefore, Emmaus Life Sciences's net margin for the quarter that ended in Mar. 2026 was -168.26%.

The historical rank and industry rank for Emmaus Life Sciences's Net Margin % or its related term are showing as below:

EMMA' s Net Margin % Range Over the Past 10 Years
Min: -6989.41   Med: -68.77   Max: 5.84
Current: -70.64

EMMA's Net Margin % is ranked better than
51.74% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs EMMA: -70.64

Emmaus Life Sciences  (OTCPK:EMMA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Emmaus Life Sciences Net Margin % Related Terms

Emmaus Life Sciences Net Margin % Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Net Margin % Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -77.37 -57.78 -12.61 -38.75 -60.16

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -96.84 -40.29 -61.46 -50.65 -168.26

EMMA vs CERO, AGTX, WINT: Net Margin % Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Net Margin % falls into.


Emmaus Life Sciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Emmaus Life Sciences's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-7.492/12.453
=-60.16 %

Emmaus Life Sciences's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.335/1.982
=-168.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -168.26% mean?
Emmaus Life Sciences (EMMA) has a Net Margin % of -168.26% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #457 out of 947 companies in the Biotechnology industry, placing it in the top 48.3%.
Is Emmaus Life Sciences' Net Margin % too high?
Emmaus Life Sciences' current Net Margin % is -168.26%. Based on the distribution chart, Emmaus Life Sciences ranks #457 out of 947 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' Net Margin % compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #457 out of 947 companies for Net Margin %. This puts Emmaus Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Net Margin % is -168.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Net Margin % is -168.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Net Margin % is -168.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.